• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nightingale joins wellbeing services county research project

HEALTHAnalyst Comment29.05.2026 klo 09.46
Antti SiltanenAnalyst
Discuss

Summary

  • Nightingale Health is participating in a research project with Etelä-Savo wellbeing services county, combining its blood analysis technology with digital lifestyle coaching.
  • The project, called Hyvinvointilahja, offers free health assessments to certain age groups and aims to evaluate the effectiveness of this model in public healthcare.
  • The initiative is limited in scope and does not immediately impact financial forecasts, but it serves as a strategic reference for potential future adoption in the public sector.
  • For Nightingale to achieve profitability, it needs to convert these pilot projects into continuous, high-volume use in public healthcare, which remains a slow-moving sector.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 5/29/2026 at 7:00 am EEST.

Nightingale Health announced on Thursday that it is participating in a research and development project initiated by the Etelä-Savo wellbeing services county, Eloisa, in which the company's blood analysis technology is combined with digital lifestyle coaching. The start of the project is the first practical step in the collaboration the parties already announced in June 2025. Although this is an encouraging opening in the public primary healthcare sector, the project is limited in scope as a research initiative, and therefore the announcement does not cause immediate changes to our forecasts.

Piloting towards public healthcare clients

In the Hyvinvointilahja project (“Wellbeing Gift”), 45-, 50-, and 55-year-olds in the Eloisa region are offered a free health assessment, and individuals with an elevated risk are referred to lifestyle counseling. The project will be implemented between March 2026 and April 2027, and it is funded by Sitra and Eloisa. Nightingale is aiming for breakthroughs in the public healthcare sector, which is a huge potential target market for the company, but at the same time, a very slow-moving and conservative sector. The project's goal is specifically to evaluate the effectiveness of the operating model before any potential wider implementation.

Financial potential will only be measured upon potential wider adoption

While the project is a strategically important reference from the public sector, its immediate financial size will likely remain quite moderate on the company's scale. In our view, turning Nightingale's business model profitable requires revenue to multiply and a continuous stream of significant commercial sample volumes. We are following the results of the project with interest, but what is decisive for the valuation and investment story is whether Nightingale can turn these fixed-term pilots into continuous, high-volume routine use in public healthcare.

 

Login required

This content is only available for logged in users

Create account

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more on company page

Key Estimate Figures06.03.

202526e27e
Revenue4.77.98.3
growth-%7.7 %68.5 %4.3 %
EBIT (adj.)-19.4-16.5-14.4
EBIT-% (adj.)-413.7 %-208.1 %-174.1 %
EPS (adj.)-0.30-0.26-0.22
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

This AI piece seems more like an advertisement for NG than a summary of a scientific article. How many seconds will it take for “headquarters...
13 hours ago
by Sakuoulu
0
In principle, it is possible, and in those scenarios, value is measured in a completely different way than through business metrics.
17 hours ago
by Puutaheinää
1
I would think that metabolomics data helps with development at any time. In this recent post, there is one example of how NH’s data can help...
17 hours ago
by The Ugly Buckling
1
AI giant Anthropic is starting to develop drugs (Claude Science). Does NH and its data have any chance of becoming a partner or similar in this...
19 hours ago
by eizbee
1
I disagree. The company is trying to build strong growth on three continents simultaneously, and the adequacy of funding is a key factor over...
22 hours ago
by Puutaheinää
1
With such small companies and revenue, there shouldn’t be any rush to appoint a CFO.
yesterday
by Pertti
0
This wasn’t exactly Nightingale (NH) news, but it reminded me to ask: where is Nightingale’s CFO? It’s been a long time without one for a listed...
yesterday
by Puutaheinää
0